High rate of Clostridium difficile among young adults presenting with diarrhea at two hospitals in Kenya

International Journal of Infectious Diseases

Volumn 74, Issue , 2018, Pages 24-28

  Oyaro, Micah O ^a   Plants Paris, Kimberly ^b   Bishoff, Dayna ^b   Malonza, Paul ^a   Gontier, Christopher S ^a   DuPont, Herbert L ^b,c,d   Darkoh, Charles ^b,c  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Antibiotics and CDI; C. difficile epidemiology; C. difficile pathogenesis; CDI in young adults; Clostridium difficile infections in Africa

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; CEFALEXIN; CEFOXITIN; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; METRONIDAZOLE; RNA 16S; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIUM CULTURE; BACTERIUM DETECTION; CLOSTRIDIUM DIFFICILE INFECTION; CROSS-SECTIONAL STUDY; DIARRHEA; FECES ANALYSIS; FEMALE; HUMAN; KENYA; MALE; MIDDLE AGED; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; TCDA GENE; TCDB GENE; TCDC GENE; YOUNG ADULT; ADOLESCENT; AGED; CHILD; CLOSTRIDIUM INFECTION; COMORBIDITY; FECES; GENETICS; HOSPITAL; ISOLATION AND PURIFICATION; MICROBIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIARRHEA; FECES; FEMALE; HOSPITALS; HUMANS; KENYA; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 85049928202     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2018.06.014     Document Type: Article

References (28)

1. Borriello, S.P., Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 41:Suppl C (1998), 13–19.
2. Carter, G.P., Douce, G.R., Govind, R., Howarth, P.M., Mackin, K.E., Spencer, J., et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog, 7(10), 2011, e1002317.
3. Curry, S.R., Marsh, J.W., Muto, C.A., O'Leary, M.M., Pasculle, A.W., Harrison, L.H., tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 45:1 (2007), 215–221.
4. Darkoh, C., DuPont, H.L., Kaplan, H.B., Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. J Clin Microbiol 49:12 (2011), 4219–4224.
5. Darkoh, C., Kaplan, H.B., DuPont, H.L., Harnessing the glucosyltransferase activities of Clostridium difficile for functional studies of toxins A and B. J Clin Microbiol 49:8 (2011), 2933–2941.
6. Fiedoruk, K., Daniluk, T., Rozkiewicz, D., Zaremba, M.L., Oldak, E., Sciepuk, M., et al. Conventional and molecular methods in the diagnosis of community-acquired diarrhoea in children under 5 years of age from the north-eastern region of Poland. Int J Infect Dis 37 (2015), 145–151.
7. Fry, P.R., Thakur, S., Abley, M., Gebreyes, W.A., Antimicrobial resistance, toxinotype, and genotypic profiling of Clostridium difficile isolates of swine origin. J Clin Microbiol 50:7 (2012), 2366–2372.
8. Geric, B., Rupnik, M., Gerding, D.N., Grabnar, M., Johnson, S., Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 53:Pt 9 (2004), 887–894.
9. Griffiths, D., Fawley, W., Kachrimanidou, M., Bowden, R., Crook, D.W., Fung, R., et al. Multilocus sequence typing of Clostridium difficile. J Clin Microbiol 48:3 (2010), 770–778.
10. Hundsberger, T., Braun, V., Weidmann, M., Leukel, P., Sauerborn, M., von Eichel-Streiber, C., Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 244:3 (1997), 735–742.
11. Johnson, S., Louie, T.J., Gerding, D.N., Cornely, O.A., Chasan-Taber, S., Fitts, D., et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 59:3 (2014), 345–354.
12. Just, I., Selzer, J., Wilm, M., von Eichel-Streiber, C., Mann, M., Aktories, K., Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375:6531 (1995), 500–503.
13. Keeley, A.J., Beeching, N.J., Stott, K.E., Roberts, P., Watson, A.J., Beadsworth, M.B., Clostridium difficile: a healthcare-associated infection of unknown significance in adults in sub-Saharan Africa. Malawi Med J 28:2 (2016), 66–69.
14. Khanna, S., Pardi, D.S., Clostridium difficile infection: new insights into management. Mayo Clin Proc 87:11 (2012), 1106–1117.
15. Kuehne, S.A., Cartman, S.T., Heap, J.T., Kelly, M.L., Cockayne, A., Minton, N.P., The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:7316 (2010), 711–713.
16. Lemee, L., Dhalluin, A., Testelin, S., Mattrat, M.A., Maillard, K., Lemeland, J.F., et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 42:12 (2004), 5710–5714.
17. Li, N., Jia, H., Yang, H., Ji, B., Liu, Y., Peng, X., et al. Preliminary screening of type IV secretion system in divergent geographic sources of Clostridium difficile. Exp Ther Med 14:5 (2017), 4405–4410.
18. Liu, X.S., Li, W.G., Zhang, W.Z., Wu, Y., Lu, J.X., Molecular characterization of Clostridium difficile Isolates in China from 2010 to 2015. Front Microbiol, 9, 2018, 845.
19. Lyerly, D.M., Saum, K.E., MacDonald, D.K., Wilkins, T.D., Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47:2 (1985), 349–352.
20. Matamouros, S., England, P., Dupuy, B., Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 64:5 (2007), 1274–1288.
21. Murray, R., Boyd, D., Levett, P.N., Mulvey, M.R., Alfa, M.J., Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. BMC Infect Dis, 9, 2009, 103.
22. Onwueme, K., Fadairo, Y., Idoko, L., Onuh, J., Alao, O., Agaba, P., et al. High prevalence of toxinogenic Clostridium difficile in Nigerian adult HIV patients. Trans R Soc Trop Med Hyg 105:11 (2011), 667–669.
23. Owens, R.C. Jr., Donskey, C.J., Gaynes, R.P., Loo, V.G., Muto, C.A., Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 46:Suppl 1 (2008), S19–31.
24. Rupnik, M., Brazier, J.S., Duerden, B.I., Grabnar, M., Stubbs, S.L., Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology 147:Pt 2 (2001), 439–447.
25. Seugendo, M., Mshana, S.E., Hokororo, A., Okamo, B., Mirambo, M.M., von Muller, L., et al. Clostridium difficile infections among adults and children in Mwanza/Tanzania: is it an underappreciated pathogen among immunocompromised patients in sub-Saharan Africa?. New Microbes New Infect 8 (2015), 99–102.
26. Voth, D.E., Ballard, J.D., Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:2 (2005), 247–263.
27. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:9491 (2005), 1079–1084.
28. Zhang, S., Palazuelos-Munoz, S., Balsells, E.M., Nair, H., Chit, A., Kyaw, M.H., Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis, 16(1), 2016, 447.